---
title: "Apogee net loss widens to $85.85 million in Q2 FY26; R&D expenses rise to $67.3 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295396444.md"
description: "Apogee Therapeutics reported a widened Q2 FY26 net loss of $85.85 million, driven by increased R&D and G&A expenses. The company holds $1.3 billion in cash. Additionally, Apogee announced its acquisition by AbbVie for $135.11 per share, valuing the equity at approximately $10.9 billion, with closing expected in Q3 2026. Phase 2 APEX Part B results supported plans to start Phase 3 trials this year."
datetime: "2026-08-10T11:06:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295396444.md)
  - [en](https://longbridge.com/en/news/295396444.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295396444.md)
generator: "portal-rs"
---

# Apogee net loss widens to $85.85 million in Q2 FY26; R&D expenses rise to $67.3 million

-   Apogee Therapeutics posted a Q2 2026 net loss of $85.85 million, widening from $66.1 million a year earlier. \* R&D expenses rose 20.82% to $67.3 million, while G&A costs climbed 39.38% to $24.34 million, both versus Q2 2025. \* Cash, cash equivalents and marketable securities totaled $1.3 billion at June 30, 2026, up from $621.2 million a year earlier. \* June 2026 deal calls for AbbVie to buy Apogee for $135.11 per share in cash, valuing equity at about $10.9 billion; closing expected Q3 2026. \* Phase 2 APEX Part B met endpoints; 65.9% on mid-dose zumilokibart achieved EASI-75 at Week 16, supporting planned Phase 3 start this year. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apogee Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608100700PRIMZONEFULLFEED9806027) on August 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [APGE.US](https://longbridge.com/en/quote/APGE.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

- [AbbVie (NYSE:ABBV) Issues FY 2026 Earnings Guidance](https://longbridge.com/en/news/297966481.md)
- [Apogee Therapeutics shares face Nasdaq suspension as company moves to delist after AbbVie merger](https://longbridge.com/en/news/297917721.md)
- [PulteGroup declares Q3 2026 dividend of R$ 0.9 per unit](https://longbridge.com/en/news/297931957.md)
- [Igua Sergipe board signs off Q2 2026 financial results](https://longbridge.com/en/news/297932404.md)
- [Pininfarina announces availability of H1 2026 interim financial report](https://longbridge.com/en/news/298044460.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**